Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

• the invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo- [3,2-fJquinoxaline derivatives of the formula I
• R 3 is H, Hal, OH, OA or O-(CH 2 ) n -Ar,
• R 4 is H, A or -(CH 2 ) n -Ar,
• R 5 is H or A
• R 6 , R 7 and R 8 are each, independently of one another, H, A or -(CH 2 ) n -Ar, R 7 and R 8 together are alternatively alkylene having from 3 to 6 carbon atoms, A is a linear or branched alkyl group having from 1 to 10 carbon atoms, Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR 5 , N(R 5 ) 2 ,
• cycloalkyl is cycloalkyl having from 3 to 10 carbon atoms
• Hal is F, CI. Br or l
• Het is a saturated, unsaturated or aromatic monocyclic or bicyclic heterocyclic radical having from 5 to 10 ring members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms, and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A,
• Het 1 is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR 5 , N(R 5 ) 2 , NO 2 , CN and/or carbonyl oxygen, n is 0, 1 , 2, 3, 4, 5, 6, 7 or 8, m is 1 or 2, o is 0, 1 , 2, 3 or 4, and their physiologically acceptable salts and solvates.
• the invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
• the compounds are nicotinic acetylcholine receptor ligands and/or serotonergic ligands.
• acetylcholine receptors Of the well-characterised class of acetylcholine receptors, some members have been implicated in certain disorders of the central nervous system.
• active ingredients which are able to interact with the acetylcholine receptor class are, for example, pilocarpine, nicotine, lobeline and epibatidine.
• nicotinic acetylcholine receptors can be divided into two main classes, depending on the sites at which they occur.
• the first class comprises the neuromuscular receptors. These are subdivided into ( ⁇ -i ⁇ -i ⁇ ) and ( ⁇ -i ⁇ i ⁇ ) receptors.
• the second class comprises the neuronal nicotinic acetylcholine receptors, which are found in the ganglia.
• the substances of the formula I are capable of interacting with each of these receptors.
• the substances of the formula I interact particularly well with the nicotinic ⁇ receptor.
• Serotonergic ligands are ligands of the 5-HT 3 receptor and/or of the 5-HT ⁇ receptor.
• 5-HT 6 receptors form a sub-family of 5-HT receptors.
• the neurotransmitter 5-hydroxytryptamine (5-HT) also known as serotonin, is an important regulatory neurotransmitter in the brain whose actions are supported by a family of receptors, which, as far as we know today, contain 13 G-protein- coupled receptors and an ion channel.
• the greatest density of serotonin 5-HT ⁇ receptors in the brain is found in the tuberculum olfactorium, in the nucleus accumbens, in the striatum, in the gyrus dentatus and in the CA1-3 regions of the hippocampus. These regions are involved to a particularly great extent in psychiatric disorders, such as, for example, schizophrenia or depression.
• psychiatric disorders such as, for example, schizophrenia or depression.
• 5-HT ⁇ antisense oligo- nucleotides causes a behaviour syndrome which corresponds to that of dopamine agonists.
• hyperactivity of the dopaminergic neurotransmitter system is pathophysiologically safeguarded in schizophrenia (dopamine hypothesis of schizophrenia).
• the efficacy of the compounds of the formula I as inhibitors of the 5-HT 3 receptor can be determined by the method of Richardson et al., Nature 1985, 316, 126 or by the method of Watling et al., European J. Pharmacol. 1988, 149, 397.
• the compounds antagonise the action of serotonin at 5-HT 3 receptors, such as, for example, the serotonin-induced Bezold-
• Jarisch reflex (method, see J. Pharm. Pharmacol., 1980, 40, 301-302 and Nature 316, 126-131 ).
• these compounds displace the sub- stance 3 H-GR65630, which is known as a selective 5-HT 3 ligand, from the homogenised tissue from the endorhinal cortex of rats (see Europ. J. Pharmacol., 1989, 159, 157-164).
• Illnesses which can be treated with the substances of the formula I thus include psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restric- tions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, and amelioration of withdrawal symptoms in nicotine dependence.
• compounds of the formula I are used in strokes and brain damage by toxic compounds.
• the compounds of the formula I and their physiologically acceptable salts are therefore suitable as therapeutic active ingredients for disorders of the central nervous system.
• the compounds are suitable for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.
• disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.
• these include, in particular, psychoses, nausea and vomiting (occurring, for example, during chemotherapeutic or radiotherapeutic treatment of cancer diseases), irritable bowel syndrome, dementia or other cognitive disorders, migraine and addiction illnesses.
• the invention relates to the compounds of the formula I and to their physio- logically acceptable acid-addition salts.
• the invention also relates to the solvates, for example hydrates or alcoholates, of these compounds.
• solvates of the compounds of the formula I is taken to mean adducts of inert solvent molecules onto the compounds of the formula I which form owing to their mutual attractive force.
• Solvates are, for example, monohydrates or dihydrates or addition compounds with alcohols, such as, for example, with methanol or ethanol.
• radicals which have an asymmetrical carbon atom which can have different configurations be introduced via the radicals R 1 to R 4 , for example 1-azabicyclo[2.2.2]oct-3-yl for R 1
• the compounds of the formula I may exist in various optically active forms or alternatively as racemates or racemate mixtures.
• the invention also relates to the compounds of the formula I according to Claim 1 and their physiologically acceptable salts and solvates as medicament active ingredients.
• the invention likewise relates to the compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as ligands of the nicotinic acetylcholine receptor.
• the invention likewise relates to the compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as serotonergic ligands.
• A is linear or branched alkyl having from 1 to 10 carbon atoms and preferably has 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
• Alkyl having from 1 to 10 carbon atoms is preferably methyl, furthermore ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl or tert-butyl, furthermore also n-pentyl, 1-, 2- or 3- methylbutyl, n-hexyl, 1-, 2-, 3- or 4-methylpentyl, n-heptyl, 1-, 2-, 3- or 4- ethylpentyl, n-octyl, n-nonyl or n-decyl.
• Alkyl is particularly preferably methyl.
• Alkylene having from 3 to 6 carbon atoms is propylene, butylene, pentylene or hexylene. Alkylene is particularly preferably butylene.
• Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR 5 , N(R 5 ) 2) NO 2 , CN,
• Ar is preferably unsubstituted or substituted phenyl, naphthyl or biphenyl, specifically preferably phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl- phenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-aminophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-(trifluoromethoxy)- phenyl, o-, m- or p-cyanophenyl, o-, m- or p
• -(CH 2 ) n -Ar is arylalkyl if Ar has one of the meanings indicated above and n is 1 , 2, 3, 4, 5, 6, 7 or 8.
• n ⁇ 0 is preferably benzyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, phenyl- heptyl, naphthylmethyl, naphthylethyl, naphthylpropyl or naphthylbutyl.
• -(CH 2 ) n -Ar is particularly preferably benzyl or phenylethyl.
• Cycloalkyl having from 3 to 10 carbon atoms is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 2,6,6-trimethyl- bicyclo[3.1.1]heptyl.
• Cycloalkyl is likewise a monocyclic or bicyclic terpene, preferably p- menthane, menthol, pinane, bornane or camphor, including all known stereoisomeric forms, or adamantyl.
• camphor this is either L-camphor or D-camphor.
• Cycloalkyl is particularly preferably 2,6,6-trimethylbicyclo[3.1.1]heptyl.
• Hal is fluorine, chlorine, bromine or iodine, particularly preferably fluorine, chlorine or bromine.
• Het is a saturated, unsaturated or aromatic monocyclic or bicyclic hetero- cyclic radical having from 5 to 10 ring members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, -[C(R 5 ) 2 ] 0 -Ar, -[C(R 5 ) 2 ] 0 -cycloalkyl, OR 5 , N(R 5 ) 2 , NO 2 , CN, COOR 5 , CON(R 5 ) 2 , NR 5 COA, NR 5 CON(R 5 ) 2 , NR 5 SO 2 A, COR 5 , SO 2 NR 5 or S(O) m A and/or carbonyl oxygen, where A, Hal, Ar and cycloalkyl have one of the meanings indicated above, and R 5 , o and m
• Het is preferably substituted or unsubstituted 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5- oxazolyl, 3-, 4- or 5-isoxazolyI, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazoIyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1 ,2,3- triazol-1-, -4- or -5-yl, 1 ,2,4-triazol-1-, -4- or -5-yl, 1- or 5-tetrazolyl, 1 ,2,3- oxadiazol-4- or -5-yl, 1 ,2,4-oxadiazol-3- or -5-yl, 1 ,3,4-thiadiazol-2- or -5-yl, 1 ,2,4-
• heterocyclic radicals may also be partially or fully hydrogenated.
• Het may thus also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5- dihydro-2-, -3-, -4- or -5-furyl, tetrahydro-2- or -3-furyl, 1 ,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1 -, -2-, -3-, -4- or -5-pyrrolyl, 2,5- dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, - 2- or -3-pyrrolyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, - 4-, -5-, -6- or -7-1 H-
• Het is particularly preferably imidazol-1-yl, 6-methoxy-1 H-indol-3-yI, pyridin- 3-yl or 4-methylpiperazin-1-yl.
• -(CH 2 ) n -Het is particularly preferably pyridin-3-yl, 6-methoxy-1 H-indol-3- ylmethyl, (4-methyl)piperidin-1-ylethyl or imidazol-1-ylethyl.
• Het 1 is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstitu- ted, disubstituted or trisubstituted by Hal, A, OR 5 , N(R 5 ) 2) NO 2> CN and/or carbonyl oxygen, where A is as defined above, and R 5 is as defined below.
• Het 1 is preferably substituted or unsubstituted 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6- pyrimidinyl, furthermore preferably 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-1 H-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7- benzopyrazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 1-, 4-, 5-, 6-, 7- or 8- phthalazinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxaliny
• heterocyclic radicals may also be partially or fully hydrogen- ated.
• Het 1 may thus also be 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5- dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrrolyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, -5-, -6- or -7-1 H-indolyl, 2,3-dihydro-1 -, -2-, -3-, -4- or -5-pyrazoiyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1 ,5-dihydroimidazol-4-on-2- or -5
• Het 1 is particularly preferably 1-azabicyclo[2.2.2]oct-3-yl, piperidin-3-yl, piperidin-4-yl or 1-methylpiperidin-4-yl. . Het 1 is very particularly preferably 1-azabicyclo[2.2.2]oct-3-yl.
• the isomers are also referred to as tautomers, i.e. they are constitutional isomers which can be converted into one another by overcoming a relatively low energy threshold.
• R 1 is hydrogen or Het 1 , where Het 1 is as defined above.
• R 1 is preferably hydrogen or 1-azabicyclo[2.2.2]oct-3-yl, particularly preferably 1 -azabicyclo[2.2.2]oct-3-yl.
• R 2 is H, A, cycloalkyl, -(CH 2 ) n -N(R 5 ) 2 , -(CH 2 ) n -OR 5 , -(CH 2 ) n -Ar or -(CH 2 ) n -Het, where R 5 is as defined below, and n may be 0, 1 , 2, 3, 4, 5, 6, 7 or 8.
• A, cycloalkyl, Ar and Het have the preferred and particularly preferred meanings indicated above, n is preferably 1 or 2.
• R 2 is preferably A, phenyl, pyridin-3-yl, 6-methoxy-1 H-indol-3-ylmethyl, 2- dimethylaminoethyl, (4-methyl)piperidin-1-ylethyl or imidazol-1-ylethyl.
• R 3 is H, Hal, OH, OA or O-(CH 2 ) n -Ar, where Hal, A, Ar and n are as defined above.
• R 3 is preferably hydrogen.
• R 4 is H, A or O-(CH 2 ) n -Ar, where A, Ar and n are as defined above.
• R 4 is preferably hydrogen.
• R 5 is H or A, where A is as defined above.
• -(CH 2 ) n -OR 5 is particularly preferably methoxymethyl.
• -(CH 2 ) n -N(R 5 ) 2 is particularly preferably 2-dimethylaminoethyl.
• R 6 , R 7 and R 8 are each, independently of one another, H, A or -(CH 2 ) n -Ar.
• R 6 is particularly preferably hydrogen.
• R 7 is particularly preferably A.
• R 8 is particularly preferably hydrogen.
• R 7 and R 8 together may also be alkylene having from 3 to 6 carbon atoms.
• R 7 and R 8 together are particularly preferably butylene.
• n 1 or 2, where m is preferably 2.
• o is 0, 1 , 2, 3 or 4.
• o is preferably 0 or 1.
• the invention accordingly relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above.
• Some preferred groups of compounds may be expressed by the following sub-formulae la to Ij, which conform to the formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which
• R R 44 iiss hhyyddrrcogen
• R 1 is Het 1 ;
• R 2 is A, -(CH 2 ) n -N(R 5 ) 2 , -(CH 2 ) n -Ar or -(CH 2 ) n -Het, R 3 is hydrogen, R 4 is hydrogen, and R 6 is hydrogen;
• R 8 is hydrogen
• R 4 is hydrogen
• R 7 and R 8 together are alkylene having from 3 to 6 carbon atoms.
• the invention relates, in particular, to the compounds according to Claim 7 and their salts and solvates.
• the compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben- Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc., New York), to be precise under reaction conditions as are known and suitable for the said reactions. Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.
• the starting materials for the claimed process can also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds of the formula I. On the other hand, it is possible to carry out the reaction in steps.
• Compounds of the formula II can be prepared, for example, by reaction of 5-nitro-1 H-indole with an oxo-substituted heterocyclic radical Het 1 in the presence of a base followed by hydrogenation.
• An example of an oxo- substituted heterocyclic radical Het 1 is 3-quinuclidinone.
• the base used is advantageously sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate or ammonia.
• the solvent selected is preferably water, lower alcohols, such as methanol o ethanol, ethers, such as tetrahydrofuran (THF) or dioxane, sulfones, such as tetramethylene sulfone, or mixtures thereof, particularly water-containing mixtures.
• lower alcohols such as methanol o ethanol
• ethers such as tetrahydrofuran (THF) or dioxane
• sulfones such as tetramethylene sulfone, or mixtures thereof, particularly water-containing mixtures.
• the hydrogenation is carried out under standard conditions, preferably in the presence of Pd/C.
• the amines of the formula III are generally known or are commercially available; the compounds of the formula III which are not known can easily be prepared analogously to the known compounds.
• oxidants are manganese oxide (MnO 2 ), hydrogen peroxide (H 2 O 2 ), ozone (O 3 ), potassium permanganate, chromium oxide, sodium chromate or potassium chromate.
• suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, N- methylpyrrolidone (NMP), dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide
• the reaction temperature is between about -10° and 150°, normally between 0° and 130°, preferably between 0° and 50°, particularly preferably room temperature.
• the reaction time is between a few minutes and several days.
• EP 450 345 (EP 450 345 B1 : column 3, line 8, to column 4, line 38).
• EP 450 345 is incorporated herein by way of reference.
• Diamines of the formula V are generally known or commercially available; the compounds of the formula V which are not known can easily be prepared analogously to the known compounds.
• V is carried out in the presence of an oxidant, under reaction conditions as described above.
• Suitable oxidants are likewise manganese dioxide (MnO 2 ), hydrogen peroxide (H 2 O 2 ), ozone (O 3 ), potassium permanganate, chromium oxide, sodium chromate or potassium chromate.
• a base of the formula I obtained can be converted into the associated acid- addition salt using an acid.
• Suitable acids for this reaction are those which give physiologically acceptable salts.
• inorganic acids for example sulfuric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, nitric acid, sulfamic acid, furthermore organic acids, specifically aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, such as formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, benzoic acid, salicylic acid, 2-phenylpropionic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonic
• the free bases of the formula I can, if desired, be liberated from their salts by treatment with strong bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate, so long as no further acidic groups are present in the molecule.
• the invention furthermore relates to the medicament active ingredients according to the invention as nicotinic acetylcholine receptor ligands and/or serotonergic ligands for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory restrictions, age- induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.
• the invention furthermore relates to pharmaceutical preparations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts or solvates.
• the compounds of the formula I here can be converted into a suitable dosage form together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and if desired in com- bination with one or more further active ingredients.
• Suitable excipients are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administra- tion and which do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc and Vaseline.
• Suitable for oral administration are, in particular, tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal administration are suppositories, suitable for parenteral administration are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical application are ointments, creams or powders.
• the novel compounds may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations.
• the preparations indicated may be sterilised and/or comprise adjuvants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colorants, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
• adjuvants such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colorants, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
• the substances according to the invention are generally administered analogously to known, commercially available preparations (for example Tae-rin), preferably in doses of between about 5 mg and 100 mg, in particular between 10 and 40 mg per dosage unit.
• the daily dose is preferably between about 0.5 and 1 mg/kg of body weight.
• the specific dose for each individual patient depends on a very wide variety of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and method of administration, on the excretion rate, medi- cament combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.
• the above-mentioned compounds of the formula I are used for the prepa- ration of medicaments, in particular medicaments which are employed for the treatment of disorders based on dysfunction of nicotinic acetylcholine receptors.
• the invention likewise relates to the use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts or solvates for the preparation of a medicament, in particular for the preparation of a medicament for the treatment of disorders in which the binding to nicotinic acetylcholine receptors results in an improvement in the clinical picture.
• the invention furthermore relates to the use of compounds of the formula according to Claim 1 and/or of their physiologically acceptable salts and solvates for the preparation of a medicament for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.
• psychoses schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compuls
• the invention furthermore relates to the use of compounds of the formula I according to Claim 1 and/or of their physiologically acceptable salts and solvates for the preparation of a medicament for the treatment of disorders that are characterised by an excess of circulating serotonin or by seroto- nergic hyperactivity, in particular of nausea or vomiting.
• 8-(1 -azabicyclo[2.2.2]oct-3-yl)-2-methyl-3,6-dihydroimidazo[4,5-e]indole is a 1 :1 mixture of the tautomeric forms 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-methyl- 3,6-dihydroimidazo[4,5-e]indole and 8-(1 -azabicyclo[2.2.2]oct-3-yl)-2- methyl-1 ,6-dihydroimidazo[4,5-e]indole.
• 0.2 mmol of ethane-1 ,2-diamine and 1 mmol of MnO 2 are added to a solution of 0.1 mmol of 3-(1-azabicyclo[2.2.2]oct-3-yl)-1 H-indol-5-ol (prepared analogously to Example 1.1 to 1.2 by reaction of 5-hydroxy-1 H-indole with 3-quinuclidinone followed by hydrogenation) in 2 ml of DMF, and the mix- ture is stirred at room temperature for 18 hours.
• Example 4 Analogously to Example 3, reaction of 9-(1-azabicyclo[2.2.2]oct-3-yl)-7H- pyrrolo[3,2-f]quinoxaline with
• Example A Injection vials
• a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 I of bidistilled water is adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.
• a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.
• a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 x 2 H 2 O, 28.48 g of Na 2 HPO x 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 I and sterilised by irradiation. This solution can be used in the form of eye drops.
• 500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.
• a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed to give tablets in a conventional manner in such a way that each tablet contains 10 mg of active ingredient.
• Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
• a solution of 1 kg of active ingredient of the formula I in 60 I of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Psychology (AREA)
• Pain & Pain Management (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Nutrition Science (AREA)
• Otolaryngology (AREA)
• Addiction (AREA)
• Child & Adolescent Psychology (AREA)
• Reproductive Health (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=7683301

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (7)

Family Cites Families (6)

• 2001
  • 2001-04-30 DE DE10121215A patent/DE10121215A1/de not_active Withdrawn
• 2002
  • 2002-03-30 EP EP02735200A patent/EP1383774B1/en not_active Expired - Lifetime
  • 2002-03-30 SK SK1447-2003A patent/SK14472003A3/sk unknown
  • 2002-03-30 CZ CZ20033195A patent/CZ20033195A3/cs unknown
  • 2002-03-30 AU AU2002310904A patent/AU2002310904B2/en not_active Ceased
  • 2002-03-30 WO PCT/EP2002/003582 patent/WO2002088143A2/en not_active Ceased
  • 2002-03-30 US US10/476,234 patent/US7279496B2/en not_active Expired - Fee Related
  • 2002-03-30 HU HU0304046A patent/HUP0304046A2/hu unknown
  • 2002-03-30 AT AT02735200T patent/ATE394404T1/de not_active IP Right Cessation
  • 2002-03-30 ES ES02735200T patent/ES2303857T3/es not_active Expired - Lifetime
  • 2002-03-30 CA CA2445834A patent/CA2445834C/en not_active Expired - Fee Related
  • 2002-03-30 DE DE60226428T patent/DE60226428D1/de not_active Expired - Lifetime
  • 2002-03-30 JP JP2002585441A patent/JP4593879B2/ja not_active Expired - Fee Related
  • 2002-04-26 AR ARP020101529A patent/AR033624A1/es not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events